Securities code: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) securities abbreviation: Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) No.: 2022031 Shenzhen Salubris Pharmaceuticals Co.Ltd(002294)
Performance forecast for the first quarter of 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2022 to March 31, 2022
2. Performance forecast:
□ turning losses into profits ▇ rising in the same direction □ falling in the same direction
The current reporting period of the project is the same period of last year
861302 million yuan – 10527025 million yuan
The operating income is 7659311 million yuan
Year on year growth: 12.45% – 37.44%
Profit attributable to listed companies: 211576700 yuan – 262727100 yuan
Net profit of shareholders: 1550579 million yuan, an increase of 36.45% – 69.44% over the same period of last year
Profit after deducting non recurring losses: 1634654 million yuan – 2123172 million yuan
Net profit after profit: 148089200 yuan, an increase of 10.38% – 43.37% over the same period of last year
Basic earnings per share: 0.19 yuan / share – 0.24 yuan / share earnings: 0.15 yuan / share
2、 Performance forecast, pre audit and communication with accounting firms
This performance forecast has not been pre audited by an accounting firm.
3、 Explanation of performance change reasons
1. The net profit attributable to shareholders of Listed Companies in this quarter increased compared with the same period of last year, mainly due to the overall growth of sales revenue. Among them, xinlitan, an innovative drug, renewed the national medical insurance catalogue after a new round of negotiations. In the first quarter, when the price decreased by nearly 30% year-on-year, the sales volume increased rapidly, and the sales volume was basically the same year-on-year; In addition, in 2021, the sales revenue of generic drugs purchased by the winning country achieved good growth. 2. In the first quarter of 2022, the impact of the company’s non recurring profit and loss on the net profit attributable to the shareholders of the listed company is expected to be about 40 million yuan to 48 million yuan, which is mainly due to the transfer of part of the equity of Sichuan Jinjiang Electronic Technology Co., Ltd. held by the subsidiary of Shenzhen Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) Biomedical Engineering Co., Ltd. to confirm the investment income of about 43.5 million yuan (finally subject to the audited financial statement data).
4、 Other relevant instructions
1. This performance forecast is the preliminary calculation result of the company’s financial department and has not been audited by the audit institution.
2. The specific financial data of the company’s performance in the first quarter of 2022 will be disclosed in detail in the report of the first quarter of 2022. Investors are reminded to pay attention to investment risks.
It is hereby announced
Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) board of directors
March 29, 2002
